Matthew Herper

In the meantime, thanks for joining us. Overcoming resistance and RevMed's next drug?

J. Craig Venter, the scientist whose relentless ambition helped turn genetics from an artisanal trade into an industrialized information machine,

He may not bear all the blame, but he leaves behind a weakened agency I have covered the FDA for the past 25 years, and so I don't say this lightly: Marty Makary was the worst commissioner in that time.

Report by UKlooks at progress on ‘innovation' and ‘invention' Here's one more sign of Eli Lilly's dominance in the drug industry: It took both top spots in a prominent ranking of pharmaceutical innovators and investors.

Partnership with HealthEx to combine genetics, lab results, and lifestyle data

Results deal blow to patient community and to drug developers Biogen, Denali Therapeutics

You're reading the web edition of ASCO in 30 Seconds, STAT's guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions

‘Two drugs in one' candidate, developed in China, is a highlight at ASCO

This is STAT's ASCO in 30 Seconds newsletter You're reading the web edition of ASCO in 30 Seconds, STAT's guide to the American Society of Clinical Oncology annual meeting.

Here is some of what you may have missed from the world's largest cancer research meeting.